The Role of Myeloid Differentiation Factor 2 in Stroke: Mechanisms and Therapeutic Potential.

Deyuan Zhu, Jihu Zhao, Qian Chen, Qiong Liu, Yibin Fang

Abstract readReview

In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Deyuan ZhuTranslational Research Institute of Brain and Brain-like Intelligence, Department of Neurovascular Disease, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.

Jihu ZhaoTranslational Research Institute of Brain and Brain-like Intelligence, Department of Neurovascular Disease, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.

Qian ChenTranslational Research Institute of Brain and Brain-like Intelligence, Department of Neurovascular Disease, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.

Qiong LiuTranslational Research Institute of Brain and Brain-like Intelligence, Department of Neurovascular Disease, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.

Yibin FangTranslational Research Institute of Brain and Brain-like Intelligence, Department of Neurovascular Disease, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.

Funding

Medical research subject of Hongkou District Health Committee 2022-28Scientific funding of Shanghai fourth people's hospital sykyqd06701Training Program for Excellent Young Clinical Medical Talents in Hongkou District HKLCYQ2024-05

6 · The paper itself

Abstract

Stroke represents a significant public health burden, ranking as a leading cause of death and disability globally. The prevalence of stroke increases with age, with ischemic stroke accounting for nearly 87% of cases globally. The pathophysiology of stroke is characterized by neuronal injury, neuroinflammation, and oxidative stress, which exacerbate brain damage and hinder recovery. Myeloid Differentiation Factor 2 (MD2), an accessory protein of Toll-like receptor 4 (TLR4), has emerged as a key player in mediating inflammatory responses in stroke. This short review discusses the molecular mechanisms by which MD2 contributes to neuroinflammation and neuronal death following stroke and highlights MD2 as a promising therapeutic target for stroke treatment. Subsequently, we investigate the potential of MD2 inhibitors, their underlying mechanisms, and the therapeutic prospects of such inhibitors in reducing stroke-induced brain damage.

Indexed as

Lymphocyte Antigen 96StrokeAnimalsHumansOxidative StressToll-Like Receptor 4LY96 protein, humanLymphocyte Antigen 96Toll-Like Receptor 4ischemic strokemyeloid differentiation factor 2neuroinflammationneuronal deaththerapeutic target

Identifiers

PMID40723833

DOI10.3390/biom15070961

PMCPMC12292982

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.